Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Velcade-refractory/intolerant Mantle Cell Lymphoma
NCT00702052Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2008
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in mantle cell lymphoma (MCL), sponsored by Novartis. Primary endpoint: Overall Response Rate up to 3.8 years. Started Aug 2008; status: completed.
02
Drugs
everolimus
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00702052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00702052.